CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 30 enrolled
Drug / intervention
Retigabine IRdrug
Likely dose
Retigabine IR 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01777139
NCT01777139Phase 3Completed
CompareCT.gov

A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855)

GlaxoSmithKline·interventional·Posted Jan 28, 2013·Updated Mar 11, 2020

In Brief

A Phase 3 clinical trial evaluating Retigabine IR for Epilepsy. Completed, enrolled 30 participants across 12 sites in 3 countries.

Detailed Summary

This is a multicentre, long-term, open-label extension (OLE) study to assess the long-term safety, tolerability and efficacy of retigabine immediate-release (IR) as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures (POS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesMalaysia, South Korea, Thailand
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 28, 2013
Enrollment StartApr 11, 2013
Primary CompletionDec 14, 2016
Study CompletionSep 13, 2017
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 13.4 years ago

Interventions

Retigabine IRdrug

Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.